Basilea Looks To Progress Cancer Pipeline As It Expands Zevtera Use

Ceftobiprole Approved In China

Switzerland’s Basilea Pharmaceutica is progressing its lead oncology candidates and a second late-stage US clinical trial of ceftobiprole in difficult-to-treat infections.    

Meticillin Resistant Staphylococcus aureus
Meticillin-Resistant S aureus (MRAS) • Source: Shutterstock

Key priorities for Switzerland’s Basilea Pharmaceutica Ltd. this year include pursuing the US Phase III study of the fifth-generation cephalosporin ceftobiprole in serious infections, obtaining interim clinical trial results for its lead oncology candidates derazantinib and lisavanbulin, and helping partner CR Gosun launch ceftobiprole in China.

The Basel, Switzerland-based drug development company expects to complete enrolment into the Phase III ERADICATE study of the fifth-generation cephalosporin, ceftobiprole in Staphylococcus aureus bacteremia by the end of this...

More from Anti-infective

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By 

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.